Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
More aggressive rhuFab V2 dosing scheme well-tolerated
Ft. Lauderdale-With use of a dose-escalating administration strategy,the anti-VEGF antibody fragment rhuFab V2 is safe and well-tolerated ineyes with neovascular AMD at doses as high as 2 mg and at a treatment frequencyas often as every 2 weeks, according to the results of a Phase I, multicenter,randomized trial presented by Philip J. Rosenfeld, MD.
Related Videos
Related Content
